In the face of rising resistance to all known antimalarials, new combination therapies will be required. This work examines potential drug-drug interactions between experimental antimalarial compounds, beginning with P218 and SJ733. Here we find that each drug is a potent killer of Plasmodium falciparum parasites on their own, and when used in combination appear to slightly act as antagonists against each other. Future work will explore other combinations to help influence future treatment strategies.